Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort
Copyright © 2021 Elsevier Ltd. All rights reserved..
BACKGROUND: Belimumab was recently approved for treatment of lupus glomerulonephritis (LN).
AIM: To evaluate renal response and its predictors in LN patients receiving belimumab in real-life.
PATIENTS AND METHODS: We considered all patients fulfilling the SLEDAI-2K renal items and/or having estimated glomerular filtration rate (eGFR)≤60 ml/min/1.73 m2, with positive anti-dsDNA and/or low C3/C4 enrolled in the multicentre Italian lupus cohort BeRLiSS (BElimumab in Real LIfe Setting Study), treated with monthly IV Belimumab 10 mg/kg over standard treatment. Primary efficacy renal response (PERR), defined as proteinuria ≤0.7 g/24 h, eGFR≥60 ml/min/1.73 m2 without rescue therapy, was considered as primary outcome. Complete renal response (CRR; proteinuria <0.5 g/24 h, eGFR≥90 ml/min/1.73 m2) was considered as secondary outcome. Prevalence and predictors of PERR were evaluated at 6, 12, 24 months by multivariate logistic regression.
RESULTS: Among the 466 SLE patients of BeRLiSS, 91 fulfilled the inclusion criteria, 79 females, median age 41.0 (33.0-47.0) years, median follow-up 22.0 (12.0-36.0) months. Sixty-four (70.3%) achieved PERR, of whom 38.4% reached CRR. Among patients achieving PERR at 6 months, 86.7% maintained response throughout the follow-up. At multivariable analysis, hypertension (OR [95%CI]: 0.28 [0.09-0.89], p = 0.032), high baseline serum creatinine (0.97 [0.95-0.99], p = 0.01) and high baseline proteinuria (0.37, [0.19-0.74], p = 0.005) negatively predicted PERR. Positive predictors of PERR at 12 and 24 months were baseline anti-Sm positivity (OR [95%CI]: 6.2 [1.21-31.7], p = 0.029; 19.8 [2.01-186.7], p = 0.009, respectively) and having achieved PERR at 6 months (14.4 [3.28-63.6]; 11.7 [2.7-48.7], p = 0.001 for both).
CONCLUSIONS: Add-on therapy with belimumab led to durable renal response in patients with LN in a real-life setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:124 |
|---|---|
| Enthalten in: |
Journal of autoimmunity - 124(2021) vom: 15. Nov., Seite 102729 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
73B0K5S26A |
|---|
| Anmerkungen: |
Date Completed 10.03.2022 Date Revised 10.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaut.2021.102729 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331416565 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331416565 | ||
| 003 | DE-627 | ||
| 005 | 20231225213419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaut.2021.102729 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331416565 | ||
| 035 | |a (NLM)34600347 | ||
| 035 | |a (PII)S0896-8411(21)00137-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gatto, Mariele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2022 | ||
| 500 | |a Date Revised 10.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Belimumab was recently approved for treatment of lupus glomerulonephritis (LN) | ||
| 520 | |a AIM: To evaluate renal response and its predictors in LN patients receiving belimumab in real-life | ||
| 520 | |a PATIENTS AND METHODS: We considered all patients fulfilling the SLEDAI-2K renal items and/or having estimated glomerular filtration rate (eGFR)≤60 ml/min/1.73 m2, with positive anti-dsDNA and/or low C3/C4 enrolled in the multicentre Italian lupus cohort BeRLiSS (BElimumab in Real LIfe Setting Study), treated with monthly IV Belimumab 10 mg/kg over standard treatment. Primary efficacy renal response (PERR), defined as proteinuria ≤0.7 g/24 h, eGFR≥60 ml/min/1.73 m2 without rescue therapy, was considered as primary outcome. Complete renal response (CRR; proteinuria <0.5 g/24 h, eGFR≥90 ml/min/1.73 m2) was considered as secondary outcome. Prevalence and predictors of PERR were evaluated at 6, 12, 24 months by multivariate logistic regression | ||
| 520 | |a RESULTS: Among the 466 SLE patients of BeRLiSS, 91 fulfilled the inclusion criteria, 79 females, median age 41.0 (33.0-47.0) years, median follow-up 22.0 (12.0-36.0) months. Sixty-four (70.3%) achieved PERR, of whom 38.4% reached CRR. Among patients achieving PERR at 6 months, 86.7% maintained response throughout the follow-up. At multivariable analysis, hypertension (OR [95%CI]: 0.28 [0.09-0.89], p = 0.032), high baseline serum creatinine (0.97 [0.95-0.99], p = 0.01) and high baseline proteinuria (0.37, [0.19-0.74], p = 0.005) negatively predicted PERR. Positive predictors of PERR at 12 and 24 months were baseline anti-Sm positivity (OR [95%CI]: 6.2 [1.21-31.7], p = 0.029; 19.8 [2.01-186.7], p = 0.009, respectively) and having achieved PERR at 6 months (14.4 [3.28-63.6]; 11.7 [2.7-48.7], p = 0.001 for both) | ||
| 520 | |a CONCLUSIONS: Add-on therapy with belimumab led to durable renal response in patients with LN in a real-life setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Belimumab | |
| 650 | 4 | |a Lupus nephritis | |
| 650 | 4 | |a Renal response | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a B-Cell Activating Factor |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a belimumab |2 NLM | |
| 650 | 7 | |a 73B0K5S26A |2 NLM | |
| 700 | 1 | |a Saccon, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Andreoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Bartoloni, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Benvenuti, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Bortoluzzi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Bozzolo, Enrica |e verfasserin |4 aut | |
| 700 | 1 | |a Brunetta, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Canti, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Cardinaletti, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccarelli, Fulvia |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccia, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Conti, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a De Marchi, Ginevra |e verfasserin |4 aut | |
| 700 | 1 | |a de Paulis, Amato |e verfasserin |4 aut | |
| 700 | 1 | |a De Vita, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Emmi, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Faggioli, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Fasano, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Fredi, Micaela |e verfasserin |4 aut | |
| 700 | 1 | |a Gabrielli, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a Gasparotto, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Gerli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Gerosa, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Govoni, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Gremese, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Laria, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Larosa, Maddalena |e verfasserin |4 aut | |
| 700 | 1 | |a Mosca, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Orsolini, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Pazzola, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Petricca, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Ramirez, Giuseppe A |e verfasserin |4 aut | |
| 700 | 1 | |a Regola, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Francesca W |e verfasserin |4 aut | |
| 700 | 1 | |a Rossini, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Scarpato, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Tani, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Ubiali, Tania |e verfasserin |4 aut | |
| 700 | 1 | |a Urban, Maria Letizia |e verfasserin |4 aut | |
| 700 | 1 | |a Zen, Margherita |e verfasserin |4 aut | |
| 700 | 1 | |a Doria, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Iaccarino, Luca |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of autoimmunity |d 1989 |g 124(2021) vom: 15. Nov., Seite 102729 |w (DE-627)NLM012637491 |x 1095-9157 |7 nnns |
| 773 | 1 | 8 | |g volume:124 |g year:2021 |g day:15 |g month:11 |g pages:102729 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaut.2021.102729 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 124 |j 2021 |b 15 |c 11 |h 102729 | ||